Mtorc1 Protein Inhibitors Pipeline Insight
DelveInsight’s, “mTORC1 Protein Inhibitors - Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in mTORC1 Protein Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
mTORC1 Protein Inhibitors Understanding
mTOR is a serine/threonine protein kinase in the PI3K-related kinase (PIKK) family that forms the catalytic subunit of two distinct protein complexes, known as mTOR Complex 1 (mTORC1) and 2 (mTORC2). mTORC1 is defined by its three core components: mTOR, Raptor (regulatory protein associated with mTOR), and mLST8 (mammalian lethal with Sec13 protein 8, also known as GβL).
Function - In order to grow and divide, cells must increase production of proteins, lipids, and nucleotides while also suppressing catabolic pathways such as autophagy. mTORC1 plays a central role in regulating all of these processes, and therefore controls the balance between anabolism and catabolism in response to environmental conditions. mTORC1 promotes protein synthesis largely through the phosphorylation of two key effectors, p70S6 Kinase 1 (S6K1) and eIF4E Binding Protein (4EBP). mTORC1 directly phosphorylates S6K1 on its hydrophobic motif site, Thr389, enabling its subsequent phosphorylation and activation by PDK1.
mTORC1 Protein Inhibitors - New mTOR-specific inhibitors came forth from screening and drug discovery efforts. These compounds block activity of both mTOR complexes and are called mTORC1/mTORC2 dual inhibitors. Compounds with this characteristics such as sapanisertib have entered clinical trials. A series of these mTOR kinase inhibitors have been studied. Their structure is derived from morpholino pyrazolopyrimidine scaffold. Improvements of this type of inhibitors have been made by exchanging the morpholines with bridged morpholines in pyrazolopyrimidine inhibitors and results showed increased selectivity to mTOR by 26000 fold.
The companies and academics are working to assess challenges and seek opportunities that could influence mTORC1 Protein Inhibitors R&D. The therapies under development are focused on novel approaches for MTORC1 Protein Inhibitors.
mTORC1 Protein Inhibitors Emerging Drugs Chapters
This segment of the mTORC1 Protein Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
mTORC1 Protein Inhibitors Emerging Drugs
Onatasertib (CC 223): Celgene
CC-223 is an orally available inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor CC-223 inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. CC-223 disrupted mitochondrial function, and induced mitochondrial permeability transition pore (mPTP) opening and reactive oxygen species (ROS) production. CC-223 is currently in phase II clinical trials for the treatment of Liver cancer; Non-small cell lung cancer; and Solid tumours.
Sapanisertib :Takeda Oncology
Sapanisertib is an investigational, oral and highly selective adenosine triphosphate-competitive mTOR kinase inhibitor that suppresses both mTORC1 and mTORC2. The drug is currently in phase 2 of clinical development for the treatment of Bladder cancer; Endometrial cancer; Fallopian tube cancer; Glioblastoma; Neuroendocrine tumours; Ovarian cancer; and other indicarions.
Further product details are provided in the report……..
mTORC1 Protein Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different mTORC1 Protein Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on mTORC1 Protein Inhibitors
There are approx. 5+ key companies which are developing the mTORC1 Protein Inhibitors. The companies which have their mTORC1 Protein Inhibitors drug candidates in the most advanced stage, i.e. phase II include, Celgene.
DelveInsight’s report covers around 5+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
mTORC1 Protein Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
mTORC1 Protein Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses mTORC1 Protein Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging MTORC1 Protein Inhibitors drugs.
mTORC1 Protein Inhibitors Report Insights
- MTORC1 Protein Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
mTORC1 Protein Inhibitors Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing mTORC1 Protein Inhibitors drugs?
- How many mTORC1 Protein Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for mTORC1 Protein Inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the mTORC1 Protein Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for mTORC1 Protein Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?